Ginkgo Bioworks (DNA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

DNA Stock Forecast

Ginkgo Bioworks stock forecast is as follows: an average price target of $7.00 (represents a -30.56% downside from DNA’s last price of $10.08) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

DNA Price Target

The average price target for Ginkgo Bioworks (DNA) is $7.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential -30.56% downside from DNA's last price of $10.08.

DNA Analyst Ratings

Buy

According to 6 Wall Street analysts, Ginkgo Bioworks's rating consensus is 'Buy'. The analyst rating breakdown for DNA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (50.00%), 1 'Hold' (16.67%), 2 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).

Ginkgo Bioworks Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 23, 2024	Mark Massaro	BTIG	$7.00	$8.30	-15.66%	-30.56%
Nov 29, 2022		Berenberg Bank	$6.00	$1.84	226.09%	-40.48%
Aug 16, 2022		BTIG	$6.00	$3.74	60.43%	-40.48%
Jun 16, 2022		Jefferies	$4.35	$2.59	67.95%	-56.85%
Mar 03, 2022	Steven Mah	Cowen & Co.	$12.00	$3.86	210.88%	19.05%

The latest Ginkgo Bioworks stock forecast, released on Aug 23, 2024 by Mark Massaro from BTIG, set a price target of $7.00, which represents a -15.66% decrease from the stock price at the time of the forecast ($8.30), and a -30.56% decrease from DNA last price ($10.08).

Ginkgo Bioworks Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$7.00
Last Closing Price	$10.08	$10.08	$10.08
Upside/Downside	-100.00%	-100.00%	-30.56%

In the current month, the average price target of Ginkgo Bioworks stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ginkgo Bioworks's last price of $10.08. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 17, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 23, 2024	BTIG	Sell	Sell	Hold
Jun 26, 2024	BTIG	Sell	Sell	Hold
May 15, 2024	BTIG	Buy	Sell	Downgrade
May 10, 2024	William Blair		Underperform	Downgrade
Aug 16, 2022	Raymond James	Outperform	Outperform	Hold
Aug 16, 2022	BTIG	Buy	Buy	Hold
Aug 16, 2022	CLSA		Sell	Downgrade
Jun 16, 2022	Jefferies	Buy	Buy	Hold
May 18, 2022	Bank of America Securities		Underperform	Downgrade
Feb 23, 2022	Goldman Sachs		Neutral	Initialise

Ginkgo Bioworks's last stock rating was published by Cowen & Co. on Sep 17, 2024. The company gave DNA a "Buy" rating, the same as its previous rate.

Ginkgo Bioworks Financial Forecast

Ginkgo Bioworks Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$34.76M	$55.43M	$80.57M	$80.70M	$98.28M	$66.40M	$144.62M	$168.41M	$148.49M	-
Avg Forecast	$77.40M	$71.60M	$60.00M	$51.00M	$62.25M	$52.61M	$49.55M	$44.37M	$44.47M	$44.99M	$43.14M	$45.97M	$42.50M	$48.08M	$71.50M	$71.73M	$88.64M	$60.35M	$78.83M	$105.67M	$94.81M	$46.00M
High Forecast	$81.99M	$75.84M	$63.56M	$54.02M	$65.94M	$55.72M	$52.49M	$46.67M	$44.59M	$45.50M	$43.14M	$45.97M	$54.23M	$48.08M	$75.74M	$75.98M	$93.90M	$60.35M	$78.83M	$105.67M	$94.81M	$46.00M
Low Forecast	$73.06M	$67.58M	$56.63M	$48.14M	$58.76M	$49.65M	$46.77M	$42.06M	$44.35M	$44.48M	$43.14M	$45.97M	$35.64M	$48.08M	$67.49M	$67.71M	$83.67M	$60.35M	$78.83M	$105.67M	$94.81M	$46.00M
# Analysts	1	1	1	1	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.82%	1.15%	1.13%	1.13%	1.11%	1.10%	1.83%	1.59%	1.57%	-

Ginkgo Bioworks's average Quarter revenue forecast for Mar 24 based on 2 analysts is $45.97M, with a low forecast of $45.97M, and a high forecast of $45.97M. DNA's average Quarter revenue forecast represents a 32.28% increase compared to the company's last Quarter revenue of $34.76M (Dec 23).

Ginkgo Bioworks EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-178.12M	$-286.39M	$-184.15M	$-191.62M	$-234.20M	$-654.81M	$-622.14M	$-684.28M	$-1.57B	-
Avg Forecast	$-77.40M	$-71.60M	$-60.00M	$-51.00M	$-62.25M	$-52.61M	$-49.55M	$-44.37M	$-44.47M	$-44.99M	$-43.14M	$-45.97M	$-42.50M	$-48.08M	$-71.50M	$-71.73M	$-88.64M	$-60.35M	$-78.83M	$-4.18B	$-94.81M	$-46.00M
High Forecast	$-73.06M	$-67.58M	$-56.63M	$-48.14M	$-58.76M	$-49.65M	$-46.77M	$-42.06M	$-44.35M	$-44.48M	$-43.14M	$-45.97M	$-35.64M	$-48.08M	$-67.49M	$-67.71M	$-83.67M	$-60.35M	$-78.83M	$-3.35B	$-94.81M	$-46.00M
Low Forecast	$-81.99M	$-75.84M	$-63.56M	$-54.02M	$-65.94M	$-55.72M	$-52.49M	$-46.67M	$-44.59M	$-45.50M	$-43.14M	$-45.97M	$-54.23M	$-48.08M	$-75.74M	$-75.98M	$-93.90M	$-60.35M	$-78.83M	$-5.02B	$-94.81M	$-46.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	4.19%	5.96%	2.58%	2.67%	2.64%	10.85%	7.89%	0.16%	16.58%	-

undefined analysts predict DNA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ginkgo Bioworks's previous annual EBITDA (undefined) of $NaN.

Ginkgo Bioworks Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-211.69M	$-302.89M	$-173.31M	$-204.97M	$-174.15M	$-669.05M	$-670.57M	$-592.59M	$-1.60B	-
Avg Forecast	$-29.26M	$-32.39M	$-48.59M	$-63.22M	$-46.76M	$-71.58M	$-76.15M	$-83.46M	$-78.58M	$-142.54M	$-161.84M	$-174.15M	$-202.02M	$-191.07M	$-180.25M	$-177.61M	$-434.96M	$-537.73M	$-376.40M	$-4.25B	$-85.14M	$-71.93M
High Forecast	$-27.12M	$-30.03M	$-45.05M	$-58.61M	$-43.35M	$-66.36M	$-70.60M	$-77.38M	$-77.49M	$-132.14M	$-150.04M	$-161.45M	$-157.13M	$-177.14M	$-167.10M	$-164.66M	$-403.24M	$-537.73M	$-376.40M	$-3.40B	$-85.14M	$-71.93M
Low Forecast	$-31.51M	$-34.89M	$-52.33M	$-68.09M	$-50.36M	$-77.09M	$-82.02M	$-89.89M	$-79.66M	$-153.52M	$-174.31M	$-187.57M	$-246.91M	$-205.80M	$-194.14M	$-191.30M	$-468.47M	$-537.73M	$-376.40M	$-5.10B	$-85.14M	$-71.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.05%	1.59%	0.96%	1.15%	0.40%	1.24%	1.78%	0.14%	18.85%	-

Ginkgo Bioworks's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DNA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Ginkgo Bioworks SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$89.22M	$82.03M	$102.34M	$111.43M	$121.42M	$435.18M	$438.43M	$434.77M	$781.63M	$28.96M
Avg Forecast	$128.76M	$119.11M	$99.81M	$84.84M	$103.56M	$87.51M	$82.43M	$73.81M	$73.98M	$74.84M	$71.77M	$76.48M	$70.70M	$79.98M	$118.94M	$119.33M	$147.46M	$95.79M	$125.13M	$167.71M	$150.49M	$31.85M
High Forecast	$136.39M	$126.17M	$105.73M	$89.87M	$109.69M	$92.70M	$87.32M	$77.63M	$74.17M	$75.69M	$71.77M	$76.48M	$90.21M	$79.98M	$125.99M	$126.40M	$156.20M	$95.79M	$125.13M	$167.71M	$150.49M	$38.23M
Low Forecast	$121.54M	$112.43M	$94.21M	$80.08M	$97.75M	$82.60M	$77.81M	$69.97M	$73.78M	$74.00M	$71.77M	$76.48M	$59.28M	$79.98M	$112.27M	$112.63M	$139.19M	$95.79M	$125.13M	$167.71M	$150.49M	$25.48M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.26%	1.03%	0.86%	0.93%	0.82%	4.54%	3.50%	2.59%	5.19%	0.91%

Ginkgo Bioworks's average Quarter SG&A projection for Mar 24 is $76.48M, based on 2 Wall Street analysts, with a range of $76.48M to $76.48M. The forecast indicates a -14.28% fall compared to DNA last annual SG&A of $89.22M (Dec 23).

Ginkgo Bioworks EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	1	1	1	2	3	1	2	2	4	2	2	2	1	1	1	1	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.13	$-0.19	$-0.09	$-0.11	$-0.09	$-0.41	$-0.41	$-0.37	$-1.05	$-0.08
Avg Forecast	$-0.56	$-0.62	$-0.93	$-1.21	$-0.90	$-1.37	$-1.46	$-1.60	$-1.50	$-2.73	$-3.10	$-3.33	$-3.87	$-3.66	$-3.45	$-3.40	$-8.33	$-10.47	$-7.33	$-8.56	$-1.66	$-1.40
High Forecast	$-0.52	$-0.57	$-0.86	$-1.12	$-0.83	$-1.27	$-1.35	$-1.48	$-1.48	$-2.53	$-2.87	$-3.09	$-3.01	$-3.39	$-3.20	$-3.15	$-7.72	$-10.47	$-7.33	$-8.56	$-1.66	$-1.40
Low Forecast	$-0.60	$-0.67	$-1.00	$-1.30	$-0.96	$-1.48	$-1.57	$-1.72	$-1.52	$-2.94	$-3.34	$-3.59	$-4.73	$-3.94	$-3.72	$-3.66	$-8.97	$-10.47	$-7.33	$-8.56	$-1.66	$-1.40
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.03%	0.05%	0.03%	0.03%	0.01%	0.04%	0.06%	0.04%	0.63%	0.06%

According to undefined Wall Street analysts, Ginkgo Bioworks's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DNA previous annual EPS of $NaN (undefined).

Ginkgo Bioworks Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.52	$70.00	13361.54%	Buy
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
DNA	Ginkgo Bioworks	$9.61	$7.00	-27.16%	Buy

DNA Forecast FAQ

Is Ginkgo Bioworks a good buy?

Yes, according to 6 Wall Street analysts, Ginkgo Bioworks (DNA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 50.00% of DNA's total ratings.

What is DNA's price target?

Ginkgo Bioworks (DNA) average price target is $7 with a range of $7 to $7, implying a -30.56% from its last price of $10.08. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ginkgo Bioworks stock go up soon?

According to Wall Street analysts' prediction for DNA stock, the company can go down by -30.56% (from the last price of $10.08 to the average price target of $7), down by -30.56% based on the highest stock price target, and down by -30.56% based on the lowest stock price target.

Can Ginkgo Bioworks stock reach $20?

DNA's average twelve months analyst stock price target of $7 does not support the claim that Ginkgo Bioworks can reach $20 in the near future.

What are Ginkgo Bioworks's analysts' financial forecasts?

Ginkgo Bioworks's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $208.78M (high $220.82M, low $197.25M), average EBITDA is $-209M (high $-197M, low $-221M), average net income is $-278M (high $-258M, low $-299M), average SG&A $347.31M (high $367.35M, low $328.13M), and average EPS is $-5.32 (high $-4.932, low $-5.73). DNA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $260M (high $275.41M, low $245.42M), average EBITDA is $-260M (high $-245M, low $-275M), average net income is $-173M (high $-161M, low $-187M), average SG&A $432.52M (high $458.16M, low $408.26M), and average EPS is $-3.32 (high $-3.078, low $-3.576).

Did the DNA's actual financial results beat the analysts' financial forecasts?

Based on Ginkgo Bioworks's last annual report (Dec 2023), the company's revenue was $251.46M, beating the average analysts forecast of $233.81M by 7.55%. Apple's EBITDA was $-864M, beating the average prediction of $-234M by 269.71%. The company's net income was $-893M, beating the average estimation of $-751M by 18.90%. Apple's SG&A was $385.02M, missing the average forecast of $388.95M by -1.01%. Lastly, the company's EPS was $-0.56, missing the average prediction of $-14.373 by -96.10%. In terms of the last quarterly report (Dec 2023), Ginkgo Bioworks's revenue was $34.76M, missing the average analysts' forecast of $42.5M by -18.23%. The company's EBITDA was $-178M, beating the average prediction of $-42.502M by 319.08%. Ginkgo Bioworks's net income was $-212M, beating the average estimation of $-202M by 4.79%. The company's SG&A was $89.22M, beating the average forecast of $70.7M by 26.19%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-3.867 by -96.64%